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Abstract
Background: Avian influenza viruses, belonging to the family Orthomyxoviridae, possess distinct
combinations of hemagglutinin (H) and the neuraminidase (N) surface glycoproteins. Typing of both
H and N antigens is essential for the epidemiological and surveillance studies. Therefore, it is
important to find a rapid, sensitive, and specific method for their assay, and ELISA can be useful for
this purpose, by using recombinant proteins.
Results: The nucleoprotein (NP) and truncated neuraminidase subtype 3 and 7 of avian influenza
virus (AIV) were expressed in Saccharomyces cerevisiae and used to develop an indirect enzyme-
linked immunosorbent assay for antibody detection. The developed assays were evaluated with a
panel of 64 chicken serum samples. The performance of NP-ELISA was compared with the
commercially available ProFlok® AIV ELISA kit. The results showed comparable agreement and
sensitivity between the two tests, indicating that NP-ELISA assay can be used for screening the
influenza type A antibody in AIV infected birds. The N3 and N7- ELISAs also reacted specifically to
their type specific sera and did not exhibit any cross-reaction with heterologous neuraminidase
subtype specific sera.
Conclusion: The study demonstrates the expression of the NP, N3, and N7 proteins of AIV in
yeast (S. cerevisiae) and their application in developing an indirect ELISA for detecting NP, N3 and
N7 antibodies from AIV-infected chicken sera. The described indirect ELISAs are rapid, sensitive,
specific and can be used as promising tests during serological surveillance.
Background
Influenza viruses belong to the Orthomyxoviridae family.
The influenza viruses are characterized into three types: A,
B and C, based on the structural (nucleoprotein [NP]) and
matrix [M] proteins ([1]. Type A viruses are further classi-
fied into subtypes based on the surface glycoproteins;
hemagglutinin (HA or H) and neuraminidase (NA or N)
[2]. Currently, sixteen HA subtypes (H1-H16) and nine
NA subtypes (N1-N9) have been recognized [3-7]. The
virus has been recovered from domestic and wild avian
species throughout the world and has high impact on
international trade in poultry and poultry products
[2,8,9].
From late 2003 to July 2009, AI outbreaks in poultry has
been reported in Asia, including China, Vietnam, Thai-
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land, India, Bangladesh and other countries ([10,11]. AIV
has become an important potential risk factor for human
health. Since May 2005, the numbers of both affected
countries and confirmed cases of influenza A (H5N1)
virus infection in humans have been increased [12].
Serological surveillance of antibodies against AIV is of
great importance in preventing and controlling AI. Identi-
fication of both H and N subtypes is highly essential for
the epidemiological and surveillance studies [13]. The
widely used agar gel immunoprecipitation (AGP) test
detects antibodies to both the NP and M proteins. How-
ever, the test has lower sensitivity as compared to the
ELISA and HI tests [14] and it requires large quantities of
both antigen and antibody to form the precipitation line.
Hemagglutination inhibition (HI) and neuraminidase
inhibition (NI) assays are the commonly used tests for
detection of H or N subtypes and both these tests are labo-
rious and time consuming. In addition, there are no
standard reagents available for these tests, which lead to
lab to lab variation in the interpretation of the result, thus
demanding alternative tests which should be more accu-
rate, reliable and replicable. HI test is also limited to
detect hemagglutinin subtype and requires working with
live virus, which is of major concern as it may allow dis-
semination of thevirus. The tests currently available for
detection of AIV, such as the Flu Detect (Synbiotics) FLU
OIA TEST (Biostar) and the Directigen FLU A kit (BD, Bio-
sciences) [15,16], are based on the detection of the viral
nucleoprotein, which is conserved in all influenza A
viruses and does not provide the information about the
circulating neuraminidase subtypes. Thus, it is important
to develop a serological assay which is safe, sensitive, spe-
cific, cost-effective, and easy to perform, especially for its
application in developing and underdeveloped countries.
Recombinant proteins of AIV have been produced in
expression systems using prokaryotic or eukaryotic host
organisms [17-21]. The commonly preferred models for
protein expression are the E. coli and insect-cell culture
systems. Yeasts expression systems are attractive alterna-
tives for the production of heterologous proteins. Their
eukaryotic subcellular organization allows them to carry
out the post-translational folding, processing and modifi-
cations required to produce bioactive mammalian pro-
teins. In addition, yeast combines the simplicity and cost-
effectiveness of bacterial expression systems and is better
than the more expensive and less convenient cell culture
systems [22]. To date, there are no reports of using yeast
expressed AIV recombinant proteins as antigens for ELISA.
To the best of our knowledge, this is the first report of
expressing NP, N3 and N7 proteins of AIV in S. cerevisiae
and the development of an indirect ELISA test.
Methods
Serum samples
A panel of sera containing 64 chicken serum samples, of
which 24 were AIV-positive and remaining 40 were AIV-
negative, was used in this study. AIV positive sera were
purchased from National Veterinary Service Laboratory,
Iowa USA (Table 1). Positive sera for Newcastle disease
(ND), infectious bursal disease (IBD) were obtained from
Synbiotics Inc., CA USA and serum for infectious bronchi-
tis (IB) was purchased from Charles River Laboratories,
MA USA. Out of 40 serum samples, 37 were from chickens
negative for AIV (Georgia Poultry Laboratory, GA USA,
and Synbiotics, Inc., CA USA) and the rest were positive
for Newcastle disease (ND), infectious bursal disease
(IBD) and infectious bronchitis (IB) obtained from Synbi-
otics and Charles River Laboratories respectively.
Cloning of AIV genes
The NP gene [A/Ck/HK/CSW161/2003 (H9N2)] was
amplified by reverse transcription-polymerase chain reac-
tion (RT-PCR) using the upstream primer NPEcoF (5'-
CGAATTCATGGCGTCTCAAGGCACCAAACGA-3') and
downstream primer NPHisR5'-CAAGCTTCAATGGTGAT-
GGTGATGATGATTGTCATACTCCT-3'). Both the primers
contained EcoRI site at their 5' and 3' end, respectively
and a 6× Histidine tag was incorporated at the C-terminus
of the NP gene. Similarly, the truncated N3 [A/mallard/
duck/ALB/279/1977 (H7N3) and N7 genes [A/pintail/
duck/ALB/303/1977 (H10N7)] were amplified using
their respective primer pairs (N3TBamF:5'-GGGATCCAT-
GACAGATGGCCCTGCTGCTAATAG-3'; N3TXhoR:5'-
CCTCGAGGCCCTTGGTTTTGACAATGAAAC-3' and
N7TBamF:5'-GGGATCCATGACCGACGGATCGGCTAG-
TAG-3'; N7TXhoR:5'-CCTCGAGTTCACTGTTATCATTC-
CAATAGTC-3').
The amplified products were cloned into the pCR2.1 vec-
tor (Invitrogen, CA, USA) following manufacturer's
instructions and called as pCR-NP, pCR-N3/N7 plasmids.
The integrity of the plasmid was verified by sequencing
the DNA using an automated DNA sequencer (Applied
Biosystems, CA, USA). The pCR-NP plasmid was digested
with EcoRI and the NP gene was cloned in the unique
EcoRI site of S. cerevisiae expression vector pESC-URA
(Stratagene, La Jolla, CA) downstream of the GAL10 pro-
moter. The amplified truncated neuraminidase subtype 3
(N3T) and 7 (N7T) genes were subcloned between BamHI
and SalI sites of pESC-URA vector downstream of the
GAL1 promoter. The inserts (~0.525 kb fragment) were
ligated in-frame with the c-Myc tag (present in the vector)
at the C terminus of N3T and N7T proteins.
Expression of NP, N3, and N7 proteins in yeast
The pESC-derived expression plasmids carrying the NP,
N3 and N7 protein-encoding sequences were transformedVirology Journal 2009, 6:158 http://www.virologyj.com/content/6/1/158
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into the S. cerevisiae (strain MYA378; Stratagene, La Jolla,
CA) using the Yeast Transformation Kit (Sigma, St Louis,
MO) following the manufacturer's instructions. Trans-
formed yeast colonies were selected for growth in syn-
thetic complete medium without uracil and expression of
the genes was induced with 2% galactose. Expression of
proteins was checked by SDS-PAGE and western blot
assays. Briefly, the yeast colonies were grown at 30°C for
three days collected by centrifugation, and resuspended in
100 μl 1× loading buffer and boiled for 5 minutes. After
centrifugation, the supernatant was analyzed by 12%
SDS-polyacrylamide gels. The gel was transferred to nitro-
cellulose (NC) membrane by electroblotting. The NC
membrane was blocked with 5% skim milk (SM) and
incubated at 37°C for 1 hour with AIV polyclonal or mon-
oclonal (polyhistidine or c-Myc) antibody (Sigma, St.
Louis, MO). After washing three times with PBST buffer
(PBS pH 7.4 with 0.1% Tween-20), the NC membrane
was incubated with alkaline phosphatase-labeled second-
ary antibody (KPL, Gaithersburg, MD). Detection was
obtained using the colorimetric substrate Fast red and
Napthol in 0.1 M Tris-HCl buffer pH 8.0.
Isolation of recombinant NP, N3, and N7 proteins from 
yeast
The  S. cerevisiae culture expressing NP protein was
expanded in uracil deficient drop-out media containing
2% galactose and was grown to an OD600 of 0.8. Large
scale cultures of 20 L were collected and the pellet was
cracked with microfluidizer. The clarified supernatant was
used for coating the ELISA plates. For N3 and N7, 2 L of
yeast cultures were centrifuged at 3,000 × g, and the pellet
(~10 gm) was resuspended in 450 ml of 0.2 N NaOH
solution, and incubated for 5 min at room temperature.
The suspension was then centrifuged at 2,500 × g for 5
min and the pellet was treated with 12.5 ml lysis buffer
[50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.02% sodium
azide, 1% NP-40, 100 μg/ml PMSF and 1 μg/ml apro-
tinin] for 30 min at 4°C, followed by centrifugation at
9000 × g for 20 min. The supernatant was collected and
stored at -80°C until use. The N3 and N7 proteins were
purified using c-Myc tagged affinity purification columns
(MBL, Japan) and the purified protein was used for coat-
ing the ELISA plates.
Enzyme-linked immunosorbent assay (ELISA)
AIV positive chicken antisera purchased from Charles
River Laboratories and negative sera obtained from Synbi-
otics Inc. was used to optimize the NP-ELISA. The crude
NP, purified N3, and N7 proteins were coated onto sepa-
rate 96-well plates in PBS (pH 8.5) overnight at 4°C. The
optimal antigen concentration and the optimal serum
dilution were determined by checkerboard titration of
each antigen (1:25, 1:50, 1:100, 1:200, 1:400,1:800,
1:1600) and antisera (1:25, 1:50, 1:100, 1:200,
1:400,1:800). The wells were washed three times with
Table 1: List of strain or source used for raising AIV serum employed in this study.
Type Strain or Source Type Strain or Source
N1 A/EQUINE-1-SW/TENN/3/76 (H7N1) H4 A/Mynah/Mass/71 (H4N8)
N2 A/TY/Mass/65 (H6N2) H5 A/TY/Wisconsin/68 (H5N9)
N3 NWS-NAV2/Nws-TY/England (H0N3) H6 A/TY/Ontario/63 (H6N8)
N4 A/TY/Ontario/6118/67 (H8N4) H7 A/TY/Oregon/71/(H7N3)
N5 NWS-N5 (H0N5) H8 A/TY/Ontario/6118/67 (H8N4)
N6 NWS-DK/ENG/56 (H0N6) H9 A/Gull/MD/4435/80 (H9N5)
N7 A/CK/Germany "N"/49 (H10N7) H10 A/CK/Germany/"N"/49 (H10N7)
N8 Nws-Eq-2 (H0N8) H11 A/DK/Memph/546/74 (H11N9)
N9 A/DK/Memph/546/74 (H11N9) H12 A/DK/Alberta/60/76 (H12N5)
H1 NJ/8/76-EQ (H1N7) H13 A/Gull/MD/704/77 (H13N6)
H2 A/Pintail/Alberta/293/77 (H2N9) H14 A/Mallard/Gurjev/263/82-A/BEL/42 (H14N1)
H3 A/DK/Ukraine/1/63 (H3N8) H15 A/Shearwater/W.Australia/2576/79 (H15N9)Virology Journal 2009, 6:158 http://www.virologyj.com/content/6/1/158
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0.05% Tween-20-phosphate-buffered saline (PBST) and
subsequently blocked with PBST supplemented with 3%
(w/v) skimmed milk powder (SMP) for 10 minutes at
room temperature (RT). The positive and negative sera
were added, followed by incubation for 30 min at RT.
Subsequently, the plates were washed three times with
PBST, followed by the addition of goat anti-chicken IgG
HRP secondary antibody diluted 1:500 (KPL, Gaithers-
burg, MD) in PBST with 0.05% gelatin. After 30 min incu-
bation at RT the plates were washed as described above,
and 100 μl/well of ABTS substrate (2, 2'-azino-bis (3-
ethylbenzthiazoline-6-sulfonic acid), (KPL, Gaithersburg,
MD) was added. After 15 min incubation, the reaction
was stopped by addition of 100 μl/well of 1% SDS. The
optical density at 405 nm (OD405) was measured with an
automated plate spectrophotometer (Thermo Lab Sys-
tems, Multiskan, Finland).
The positive threshold and specificity tests
The ELISA plates were coated with optimal NP/N3/N7
antigen concentration and sera at the optimal dilution
were added. The ELISA was performed as described above.
The 37 negative sera were used to establish the endpoint
cut-off value as the mean OD405 of the 37 negative sera
plus 3 standard deviations (mean+3SD). To determine the
specificity of NP/N3/N7-ELISA, a panel of sera positive for
Newcastle disease, infectious bronchitis and infectious
bursal disease was tested.
Optimal Positive/negative ratio and Standard curve
The standard curve was constructed using the P/N ratio
method, according to Briggs and Skeeles [23]. Briefly, the
OD405 value of the positive serum (P value) was divided
by the OD405 value of the pooled negative sera (N value).
A regression line was constructed for each serum sample
and the dilution at which P/N = 1 was determined. This
dilution was called ELISA titre (ET) and was determined
for each serum sample. According to Briggs et al. [24], two
points were recorded from the regression lines for each
serum sample, the P/N ratio at 1:100 dilution and the
ELISA titre. Using these two points, the ETs were plotted
against P/N ratios at 1:100 and the prediction equation
was determined.
Results
Expression of the recombinant AIV protein
The expression of the NP, N3 and N7 genes was induced
by 2% galactose and the yeast samples were collected after
72 hours. Subsequently, the yeast lysates were analyzed by
Western blot analysis. The NP protein reacted specifically
at approximately 64 kD position when probed with poly-
histidine MAb (Fig 1a). The N3 and N7 proteins gave spe-
cific bands at ~32-35 kD position with c-Myc MAb (Fig
1b). The blots were also probed with AIV polyclonal anti-
body and the proteins reacted at the expected position
(NP at 64 kD and N3/N7 at 32-35 kD position; data not
shown). The N3 and N7 proteins were purified using c-
Myc affinity purification gel. The protein concentration of
NP and purified recombinant N3T/N7T was measured
and the samples were stored at -80°C until use.
Optimization of ELISA Procedure
To determine the optimal concentration of the antigen
and the test serum, checkerboard titration was performed.
The recombinant proteins were immobilized on ELISA
plates in two-fold serial dilution ranging from 1:50 to
1:3200 and the antisera was also diluted in serial two-fold
dilutions ranging from 1:25 to 1: 3200. The optimal anti-
gen concentration of NP, N3 and N7, as determined by
checkerboard titration, was 80 μg/ml (1:400), 60 μg/ml
(1:100) and 50 μg/ml (1:100), respectively (Fig 2a). The
optimal serum dilution was obtained by serial titration of
high positive serum (OD ≥ 1) and the pooled negative
serum from dilution 1:25 to 1:12800. The OD405 was
plotted against the dilutions and the dilution 1:100 was
selected as the dilution for determining the P/N ratio as at
this dilution the OD of the negative serum was very low,
whereas the positive serum had a high OD405 reading. To
test the optimal coating buffer, 0.05 M bicarbonate/car-
bonate buffer (pH 9.6), PBS (pH 7.4) or PBS (pH 8.5) was
screened. It was found that PBS (pH8.5) was the best coat-
ing buffer for immobilization of the proteins.
The ELISA positive threshold
The end-point cut-off was established by titration as the
mean OD405 value of the 37 negative sera plus 3 standard
deviations (mean + 3SD). The OD405 values of sera
ranged from 0.135 to 0.190. With NP antigen, the mean
OD405 value and SD were 0.163 and 0.031, respectively.
Thus, the positive threshold determined for NP-ELISA was
0.256. A serum sample was considered positive when its
OD405 value at optimal dilution (1:100) was greater than
the positive threshold. Similarly, for N3 and N7-ELISA the
end-point cut-off value determined was 0.341 and 0.413,
respectively.
Specificity tests
The specificity of NP-ELISA was evaluated by testing with
panel of sera containing antibodies against AIV, NDV, IBV
and IBDV. The results show that the NP-ELISA reacted spe-
cifically with all the 24 AIV-positive sera and there was no
cross-reaction with antisera against NDV, IBDV and IBV.
The specificity of the N3 and N7 antigens was tested using
the AIV sera, which are positive for all nine N subtypes
and 15 H subtypes (Table 1). The antigens reacted specif-
ically to their respective serum and did not cross-react
with any heterologous sera. Both the antigens did not
react with the antisera against IBDV, IBV and NDV (Fig. 3a
and 3b). This result demonstrates that the antigens have
high specificity.Virology Journal 2009, 6:158 http://www.virologyj.com/content/6/1/158
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Standard curve
The regression line of each serum was constructed using
the P/N ratio (data not shown). The ET of each serum was
calculated from this analysis and a standard curve [y (ET)
= 1.004x (P/N value at 1:100 serum dilution) + 4.0233, R2
= 0.9336 was developed (Fig. 2b). The correlation coeffi-
cient (r value) between ET and P/N at 1:100 reached at
0.9336, indicating that single serum dilution can be used
to derive the ELISA titers of antibodies.
Comparisons of NP-ELISA with ProFlok PLUS test
The NP-ELISA was compared with the commercially avail-
able ProFlok PLUS test kit (Synbiotics Inc., CA USA), the
results revealed comparable sensitivities, specificities and
overall agreements (Table 2). The NP-ELISA showed 98%
agreement and 97% specificity with the ProFlok PLUS
test.
Discussion
The accurate and prompt diagnosis of AIV infection in
birds is a critical component of surveillance and disease
control strategy. Currently, virus isolation in embryo-
nated eggs or in cell culture followed by subtyping are
considered as the standard protocol for detecting avian
influenza virus. However, the conventional culture
method requires special collection and transport condi-
tions to maintain the viability of the virus and the results
may take 1 to 2 weeks, by that time the results may not be
relevant. Molecular methods, such as reverse transcription
polymerase chain reaction [25-29] real-time RT-PCR [30-
34], RT-PCR enzyme-linked immunosorbent assay (RT-
PCR-ELISA) [5,35-37], have also been used for AIV diag-
nosis. Real-time PCR assays and a DNA microarray analy-
sis for the detection of influenza virus have also been
developed [38] but it is useful only as a supplement to
PCR-based diagnostic methods. Although, these methods
are rapid, sensitive, and specific but the test results often
need to be confirmed by additional tests, such as sequence
analysis of the PCR-amplified products.
Additionally, a recent report documents the failure of real-
time RT-PCR protocol [39], currently used in national
avian influenza surveillance programs, to detect subtype
H7 avian influenza viruses isolated from wild birds. The
Immunoblot analysis of yeast lysate from recombinant yeast clones Figure 1
Immunoblot analysis of yeast lysate from recombinant yeast clones. The proteins were separated by SDS-PAGE on a 
12% gel, blotted on to nitrocellulose, reacted with respective antibodies, and detected with colorimetric substrate Fast red and 
napthol alkaline phosphatase (Fig. 1a). Immunoblot of nucleoprotein (NP) probed with polyhistidine monoclonal antibody. Lane 
1, molecular weight marker and lane 2, recombinant yeast cell lysate expressing (NP) (Fig. 1b). Immunoblot of truncated neu-
raminidase 3 (N3T) and neuraminidase 7 (N7T) probed with c-Myc monoclonal antibody. Lane 1, molecular weight marker; 
lane 2, recombinant yeast expressing N3T; lane 3, affinity purified N3T; lane 4, recombinant yeast expressing N7T; lane 5, affin-
ity purified N7T. The position of the marker proteins in kD (right) are indicated.Virology Journal 2009, 6:158 http://www.virologyj.com/content/6/1/158
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a. Serial dilution of antigens from 1:50 to 1:3200 Figure 2
a. Serial dilution of antigens from 1:50 to 1:3200. All antibodies are at dilution 1:100. Selected Ag concentration for NP 
(1:400 dilution), N3 and N7 (1:100 dilution) antigen for cross-reactivity study are 80 μg/ml, 60 μg/ml and 50 μg/ml, respec-
tively. b. Linear regression of ELISA titre and positive/negative ratio (P/N) ratio of 1:100 serum dilution. The 
regression equation y = 1.004x + 4.0233 (r = 0.936) is shown, where y is the ELISA titre of an individual serum sample, and x is 
the P/N value at 1:100 serum dilution.
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Reactivity of N3T and N7T antigens with (a) neuraminidase-positive AIV serum and (b) hemagglutinin-positive AIV serum Figure 3
Reactivity of N3T and N7T antigens with (a) neuraminidase-positive AIV serum and (b) hemagglutinin-positive 
AIV serum. The ELISA plates were coated with N3T and N7T antigens at 60 μg/ml and 50 μg/ml, respectively. The coated 
plates were reacted with serum samples at single 1:100 dilution and incubated for 30 min at room temperature, washed three 
times with PBST (PBS with 0.05% Tween-20), followed by 30 min incubation with goat anti-chicken IgG HRP-conjugated sec-
ondary antibody. The reaction was developed with ABTS (2, 2'-Azinobis [3-thylbenzothiazoline-6-sulfonic acid]-diammonium 
salt) substrate, stopped after 15 minutes with 1% SDS, and the plates were read in a spectrophotometer using the filter at 405 
nm.
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findings depict the unreliability of the test for surveillance
programs and elucidate the need for new reliable diagnos-
tic testing methods. Antigen capture immunoassay has
been another commonly used tool for the diagnosis of
AIV [40,41]. The antigen capture tests available are
intended for testing AIV infection in humans but are also
being used for veterinary purposes. Almost all the tests tar-
get the well conserved nucleoprotein and do not provide
the information about the circulating neuraminidase sub-
types. Surveillance for avian influenza becomes much
more difficult because of the inability to differentiate the
infected from vaccinated animals (DIVA). The DIVA strat-
egy, although originally proposed in 1986 [42], has only
been recently put into practice. Among the different DIVA
strategies, one approach is to use an inactivated oil emul-
sion vaccine containing the same hemagglutinin (H) sub-
type as the field virus, but a heterologous NA subtype.
Serologic surveillance can then be performed for the
homologous NA subtype as evidence of natural infection.
This novel strategy was first used in Italy in 2000 during
an H7N1 outbreak where the turkeys were primarily vac-
cinated with an H7N3 vaccine. The only field validated
DIVA test, based on indirect immunofluorescence assay
[43,44], has limitations to be set up as high throughput
screening test and the assay requires subjective interpreta-
tion of the results. Thus, it is important to develop a sero-
logical assay for DIVA, which is sensitive, specific, cost-
effective, and easy to perform, especially for its applica-
tion in developing and underdeveloped countries.
In the present study, attempts were made to develop
ELISA for detecting antibodies against N3, N7 and NP
protein of AI viruses. Neuraminidase proteins are insolu-
ble and very difficult to express. Moreover, they share high
percentage similarity which makes it difficult to utilize
these proteins in ELISA system. We successfully expressed
truncated N3 and N7 proteins in S.cerevisiae in a way to
minimize the cross-reaction between the other neuramin-
idase types. Further, we used these proteins to develop
indirect ELISA for detecting antibodies against N3 and N7.
The specificity of the N3 and N7 antigens was tested using
the AIV sera, positive for all nine N types and 15 H types.
The antigens reacted specifically to their respective serum
and did not cross-react with any heterologous sera or
exhibited negative reactivity with antisera against IBDV,
IBV and NDV. The high specificity of N3 and N7 ELISA
demonstrates their suitability to be used for differentiat-
ing infected and vaccinated birds.
The other ELISA we developed in this study is based on
nucleoprotein (NP), which is highly conserved among AI
and can be used as candidate diagnostic antigen because
of its group and type specificity. There are previous reports
of NP ELISA [17,18,45,46], which use either monoclonal
antibodies or the recombinant proteins that are expressed
in E.coli and baculovirus. In this study, we exploited the
advantages of yeast expression system. The full-length NP
protein expressed in S. cerevisiae was used to develop an
indirect ELISA assay to detect AIV type-specific antibody.
The ELISA developed in this study is cost-effective and can
be performed at a single serum dilution, thus reducing the
error inherent to serial dilutions. The result of compara-
tive evaluation among NP-ELISA and ProFlok PLUS ELISA
showed 98% agreement and 97% specificity, proving that
the NP-ELISA system developed in this study is as effective
as the commercially available one.
In the present study, we utilized the P/N ratio regression
lines to derive the predication equation from which the
NP-ELISA titre (ET) of a serum sample could be deter-
mined using one dilution. The co-relation coefficient (r
value) between ET and P/N at 1:100 reached at 0.9336,
indicating that the ELISA titres of antibodies could be
derived at one serum dilution. The NP-ELISA can rapidly
evaluate levels of antibodies to AIV and is suitable to
detect large numbers of serum samples that would pro-
vide scientifically relevant information during a surveil-
lance program to control AIV infections in poultry.
To further strengthen this study, the ELISA system devel-
oped based on yeast-expressed antigens was compared
with another ELISA system based on baculovirus-
expressed antigens (NP, N3, and N7). The recombinant
protein expressed in insect cell culture system showed
high level of background as compared to the yeast
expressed proteins (data not shown), suggesting its
unsuitability to be used in indirect ELISA system. A differ-
ent approach was tried for protein extraction for N3 and
N7 from yeast (0.2 N NaOH) and it did not have any neg-
ative effect on the quality of the product. This method is
simple and relatively inexpensive and bypasses the neces-
sity of the microfluidizer and glass-bead or enzymatic dis-
ruption of the yeast cell wall without compromising the
quality and quantity of the extracted protein.
Conclusion
In conclusion, this study demonstrated the expression of
the NP, N3, and N7 proteins of AIV in yeast (S. cerevisiae)
and their application in developing an indirect ELISA to
Table 2: Comparative evaluation of NP-ELISA with ProFlok 
PLUS ELISA kit for detection of anti-AIV antibodies.
Test Na % agreementb % sensitivityc % specificityd
NP-ELISA 64 98 (63/64) 100 (24/24) 97 (40/41)
a Number of antisera tested.
b (no. of samples positive by both method + no. of samples negative by 
both methods)/total no. samples × 100.
c True positive/(true positive + false negative) × 100.
d True negative/(true negative + false positive) × 100Virology Journal 2009, 6:158 http://www.virologyj.com/content/6/1/158
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detect NP, N3 and N7 antibodies from AIV-infected
chicken sera. With the high degree of conservation and
group-specificity of NP, the NP-ELISA developed in this
study could detect AI antibodies to all H (1-15) and N (1-
9) subtypes. The N3 and N7 ELISAs reacted specifically to
their type-specific sera and exhibit no cross-reactivity to
other neuraminidase subtypes, indicating high specificity.
Furthermore, the tests can be completed within 2 hours
and the ELISA system developed in this study could serve
as a rapid, accurate and inexpensive diagnostic tool during
surveillance and epidemic outbreaks.
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